Phase III study evaluates addition of rituximab to ACVBP chemotherapy in low-risk diffuse large B-cell lymphoma
Source: Ann Oncol
Area: News
According to the results of a Phase III study, the addition of rituximab to ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone) chemotherapy leads to improved event-free survival (EFS) in younger patients with low-risk localised diffuse large B-cell lymphoma (DLBCL).
The authors note that controversy concerning the best treatment for localised low-risk DLBCL still remains, especially as chemo-immunotherapy has become the new standard. The LNH 93-01 study previously showed that young patients treated for localised low-risk DLBCL with the dose-intense ACVBP reg...
Source: NeLM - News - January 7, 2013 Category: Drugs & Pharmacology Source Type: news
Addition of abiraterone acetate to prednisone improved fatigue in patients with prostate cancer
Sternberg CN. Ann Oncol. 2012;doi:10.1093/annonc/mds585. (Source: HemOncToday.com)
Source: HemOncToday.com - January 3, 2013 Category: Cancer & Oncology Source Type: news
